This is an AI-generated daily briefing on the latest developments in HEOR, HTA, and market access. I've found it genuinely useful and decided to make it public.
This episode examines US pricing pressures on PBMs and discount programs, the growing importance of biomarker-driven therapies in HEOR strategies, and how M&A is accelerating differentiated drug development.
This episode examines how US healthcare system strain impacts drug reimbursement, the HEOR implications of administration innovations like subQ Leqembi, and the evolving competitive landscape in oncology and psoriasis treatments.
FDA grants Trodelvy accelerated approval with RWE conditions, CMS implements Part D step therapy, NICE reverses Orkambi rejection using RWE, and EU launches JCA for AI diagnostics.
Examining emerging HTA frameworks in the GCC, Brazil's pricing shifts, Africa's RWE adoption, Australia's digital health challenges, and Japan's gene therapy evidence strategies.
Listen Spotify AppleEU JCA procedural delays, medical device expansion, transatlantic evidence challenges, and ADC portfolio implications.
Listen Spotify AppleExamining divergent HTA approaches across emerging markets, with contrarian views on RWE utility and gene therapy valuation.
Listen Spotify AppleAnalysis of latest JCA reports, CDF recommendations, NICE reversals, and cross-jurisdictional regulatory challenges with HEOR implications.
Listen Spotify AppleAnalysis of emerging JCA reports, CDF recommendations, NICE reversal on MRD endpoints, and transatlantic regulatory divergence with HEOR implications.
Listen Spotify AppleEU JCA reports reveal methodological tensions, ADC CDF recommendations signal HTA gaps, NICE reversals challenge MRD endpoints, and regulatory divergence complicates HEOR strategies.
Listen Spotify AppleExamining evolving HTA methodologies in Asia-Pacific, RWE adoption challenges in emerging markets, digital therapeutics evidence gaps, and orphan drug RWE complexities.
Listen Spotify AppleThis episode covers PRAC valproate conclusions, HTA methodological updates in the Middle East, Canadian pricing policy developments, RWE integration challenges in Latin America, and gene therapy HEOR strategies in Asia.
Listen Spotify AppleAnalysis of recent JCA reports, NICE reversals, and transatlantic regulatory divergences with HEOR implications.
Listen Spotify AppleDeep dive into emerging JCA assessments, ADC portfolio implications, surrogate endpoint reversals, transatlantic regulatory crises, and pharmacovigilance precedents.
Listen Spotify AppleExamining gene therapy cost-effectiveness hurdles, RWE integration in HTA, PRO utility in value assessments, and evolving HTA approaches for digital health technologies.
Listen Spotify AppleExamining emerging market HTA thresholds, orphan drug RWE demands, digital therapeutics evidence gaps, geopolitical HTA challenges, and precision medicine HEOR shifts.
Listen Spotify AppleExamining evolving HTA methodologies in emerging markets, pricing pressures in Canada, RWE adoption hurdles in Latin America, and gene therapy evidence strategies in Asia-Pacific.
Listen Spotify AppleEMA CHMP approves eight treatments including rare disease; MHRA-NICE issues first aligned guidance; EU JCA scales up to 50 assessments with capacity challenges.
Listen Spotify AppleJCA reports reveal HTA evolution, while ADC evidence gaps and regulatory divergence challenge commercial strategies.
Listen Spotify AppleExamining evolving HTA evidence demands, gene therapy value hurdles, and IRA-driven HEOR shifts. Contrarian perspectives on RWE adoption and evidence generation priorities.
Listen Spotify AppleExamining FDA accelerated oncology approvals, EMA adaptive trial updates, NICE's new cell gene therapy framework, and emerging Asia-Pacific HTA collaboration.
Listen Spotify AppleInterim CDF recommendations for ADCs, NICE reversal on MRD endpoints, regulatory crises, JSC submissions, and EMA emergency trials.
Listen Spotify AppleExamining regulatory divergence impacts on HEOR strategies and recent NICE reversals on MRD endpoints.
Listen Spotify AppleExamining PRAC valproate conclusions, EU JCA capacity expansion, EMA emergency trial frameworks, oral semaglutide UK access, and tovorafenib JCA procedural timelines.
Listen Spotify AppleEpisode 34 unpacks the publication of Europe's first completed JCA report for tovorafenib and what it signals for submissions in the pipeline, the MHRA approval of oral semaglutide and the distinct NICE appraisal challenge it creates, AstraZeneca's camizestrant caught between EU approval and US ODAC rejection, and the PRAC's conclusions on paternal valproate exposure. Marcus and Sara disagree on whether the JCA's handling of indirect comparisons is reassuring or a false comfort, and on whether the camizestrant EU approval is strategically premature.
Listen Spotify AppleEpisode 33 covers NICE's interim CDF recommendation for mirvetuximab soravtansine in platinum-resistant ovarian cancer, the D-VRd reversal and what it signals about population-segmented cost-effectiveness modelling, the convergent avacopan regulatory crisis spanning MHRA, NEJM, PRAC and FDA, and the PRAC's valproate paternal exposure conclusion — a precedent-setting decision to maintain precautions despite explicitly inconsistent evidence.
Listen Spotify AppleEpisode 32 covers the publication of the tovorafenib JCA report and what its procedural timeline means for submission planning, the operational launch of medical device JCAs in June 2026, the newly opened JSC window, and the camizestrant case — where the EMA and FDA have reached categorically different conclusions from the same dataset, creating one of the most complex active HEOR files in oncology.
Listen Spotify AppleEMA's PRAC concludes valproate neurodevelopmental risk remains uncertain while EU JCA programme scales to 50 assessments in 2026. Emergency clinical trial guidance opens for consultation as oral GLP-1 approvals expand market access complexity.
Listen Spotify AppleThe EU JCA framework expands into medical devices this month while MHRA-NICE alignment delivers its first coordinated guidance. Europe's HTA infrastructure shows sustained momentum across multiple operational tracks.
Listen Spotify AppleThe UK's MHRA-NICE aligned pathway delivers first guidance this month with 27 early adopter companies, while the EU publishes its second JCA report on tovorafenib. These developments signal coordinated evolution in European HEOR infrastructure prioritizing accelerated patient access.
Listen Spotify AppleThe EU published its first joint clinical assessment report for tovorafenib, marking a milestone in HTA coordination. CHMP approval patterns show a pipeline increasingly skewed toward rare diseases and indication extensions over novel molecules.
Listen Spotify AppleThe EU published its first Joint Clinical Assessment report for tovorafenib while EMA approved oral semaglutide for weight management. JCA capacity constraints emerge as demand for scientific advice exceeds available slots.
Listen Spotify AppleCHMP's May approvals reveal a structural shift toward rare disease development while the Critical Medicines Act introduces mandatory supply chain transparency requirements. AI maintains its dominance in HEOR methodology as NICE expands cardiovascular and digital health guidance.
Listen Spotify AppleMedical device Joint Clinical Assessments begin in June 2026 as the EU HTA Regulation expands beyond oncology medicines. FDA approves first-in-class aldosterone synthase inhibitor baxdrostat while ISPOR signals a shift toward evidence judgment over generation.
Listen Spotify AppleNICE's revolutionary diabetes guideline makes SGLT-2 inhibitors first-line therapy while EU HTA regulation expands to high-risk medical devices. FDA accelerated approvals surge and EU clinical trial acceleration shows early progress toward 2030 targets.
Listen Spotify AppleMarcus and Sara examine the CHMP's May session showing 42% orphan designation rates and debate whether oral semaglutide represents genuine innovation or market expansion. They clash over emergency regulatory collaboration priorities and disagree on JCA capacity constraints for specialty medicines.
Listen Spotify AppleNICE approves third DMD treatment givinostat via Innovative Medicines Fund while CHMP's May output signals structural shift toward rare disease therapies. ISPOR 2026 highlights HEOR's expanding role in policy and value frameworks amid accelerating orphan designation trends.
Listen Spotify AppleEuropean Parliament and Council reach provisional agreement on Critical Medicines Act while EMA approves first RNA-based veterinary vaccine. ISPOR's latest trends report signals the shift from data production to evidence judgment as the new evaluation criterion.
Listen Spotify AppleMultiple first-in-class therapies create new HEOR value demonstration challenges while industry increasingly funds academic research to support policy positions. EMA's annual report reveals optimization of medicines assessments and HTA regulation coordination progress.
Listen Spotify AppleEMA's CHMP delivered eight approvals including nerandomilast for pulmonary fibrosis while the Critical Medicines Act reached provisional political agreement. EU HTA capacity building expands with multilingual eLearning modules as joint clinical asses
Listen Spotify AppleNICE transforms guidance selection with unified prioritisation framework and EQ-5D-5L implementation while EMA shows regulatory momentum with eight May approvals. The episode examines operational impacts on evidence strategy and market access plannin
Listen Spotify AppleCHMP's May session approved eight medicines including oral semaglutide, signaling structural changes in European drug development. Medical device JCAs launch in June while AI tops ISPOR's 2026 trends report.
Listen Spotify AppleMultiple first-in-class therapies create new HEOR value demonstration challenges while industry increasingly funds academic research to support policy positions. EMA's annual report reveals optimization of medicines assessments and HTA regulation coo
Listen Spotify AppleCHMP's May session approved eight medicines including oral semaglutide, signaling structural changes in European drug development. Medical device JCAs launch in June while AI tops ISPOR's 2026 trends report.
Listen Spotify AppleMedical device JCAs begin this month as NICE refines implementation guidance and biosimilar value assessment approaches. The hosts disagree on whether NICE's procedural simplifications strengthen or weaken evidence standards.
Listen Spotify AppleEMA's CHMP approved eight medicines in May with heavy focus on rare diseases and specialty indications. NICE reveals implementation details for threshold increase while JCA capacity constraints intensify with only 17 scientific advice slots available.
Listen Spotify AppleMedical device JCAs launch in June as NICE implements new prioritisation framework. Trump's MFN commitments clash with reality as pharma raises prices on over 350 products.
Listen Spotify AppleThe EU Critical Medicines Act positions EMA as central authority for supply chain assessments across 200+ substances. AI jumps to #1 in ISPOR trends while NICE advice cuts appraisal timelines by three months.
Listen Spotify AppleNICE's first QALY valuation update in over a decade shows cancer medicines becoming more cost-effective while quality-of-life therapies face higher ICERs. Meanwhile, JCA expansion into medical devices and new NICE prioritisation frameworks signal tighter evidence requirements across the board.
Listen Spotify AppleLSE expert challenges the new UK aligned drug approval pathway as industry-favoring while EU reports progress on 2030 clinical trial targets. NICE approves first HER2-targeted therapy for bile duct cancer as regulatory reforms reshape the clinical research landscape.
Listen Spotify AppleThe EU Critical Medicines Act's provisional agreement introduces supply chain resilience metrics into HTA frameworks, while NICE advances systematic technology adoption and new prioritisation criteria. EMA maintains strong approval rates as European HTA bodies expand beyond traditional pharmacoeconomic assessments.
Listen Spotify AppleNICE transforms guidance selection with unified prioritisation framework and EQ-5D-5L implementation while EMA shows regulatory momentum with eight May approvals. The episode examines operational impacts on evidence strategy and market access planning.
Listen Spotify AppleEMA's CHMP delivered eight approvals including nerandomilast for pulmonary fibrosis while the Critical Medicines Act reached provisional political agreement. EU HTA capacity building expands with multilingual eLearning modules as joint clinical assessments scale to 35 oncology reviews despite persistent bottlenecks.
Listen Spotify AppleHTACG publishes crucial data transparency principles distinguishing commercially confidential information for joint clinical assessments. NICE launches unified prioritisation framework with eight principles from public dialogue, while EMA approves challenging orphan medicines and EFPIA raises MFN pricing access concerns.
Listen Spotify AppleThe EU reaches provisional agreement on the Critical Medicines Act while EMA advances key approvals including nerandomilast for pulmonary fibrosis. HTACG clarifies JCA data transparency requirements and NICE expands semaglutide access for cardiovascular risk reduction.
Listen Spotify AppleThe EU Critical Medicines Act reaches political agreement, reshaping how Europe approaches drug supply security and evidence requirements. The MHRA-NICE aligned pathway goes live — Marcus and Sara examine what both mean for evidence strategy teams.
Listen · ~15 min Spotify AppleNICE approves givinostat for Duchenne muscular dystrophy — the third DMD treatment through the system, benefiting around 530 people in England. Evidence suggests it may delay loss of walking ability by around five years versus established care.
Listen · ~12 min Spotify AppleExamining regulatory divergence impacts on HEOR strategies and recent NICE reversals on MRD endpoints.
Listen Spotify AppleHTA digital expansion and biosimilar strategy developments in the European market access landscape.
Listen Spotify AppleSubscribe on your platform of choice — or come back here.